Financial burden of household out-of pocket health expenditure in Viet Nam: Findings from the National Living Standard Survey 2002–2010

Minh, Hoang Van; Phượng, Nguyễn Thị Kim; Saksena, Priyanka; James, Chris; Xu, Kun

doi:10.1016/j.socscimed.2012.11.028

Cited by 191 publications

(194 citation statements)

References 7 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…However, after nearly 20 years of implementation and continuous amendments, a number of studies have indicated the modest benefits of health insurance in helping patients away from catastrophe of medical expense. [22][23][24] In fact, out-of-pocket payment was too high 23 and no statistically significant effect of health insurance on the level of out-of-pocket payment was found. In addition, payments, Nguyen 22 did not find any.…”

Section: Discussionmentioning

confidence: 93%

An analysis of out-of-pocket costs associated with hospitalised injuries in Vietnam

et al. 2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

An analysis of out-of-pocket costs associated with hospitalised injuries in Vietnam

et al. 2015

View full text Add to dashboard Cite

“…The incidence of CHE among households with cancer patients in South Korea was 39.8%, lower than that of CHE in China 7. Besides CHE among cancer patients, a study in Vietnam showed that the number of households with CHE and impoverishment increased during the period of 2002‐2010 25. In Nepal, about 14% households were faced with CHE 26…”

Section: Discussionmentioning

confidence: 99%

How great is current curative expenditure and catastrophic health expenditure among patients with cancer in China? A research based on “System of Health Account 2011”

et al. 2018

View full text Add to dashboard Cite

In recent years, the incidence and mortality of cancer have witnessed a dramatic increase. Cancer has already caused severe economic burdens on society, especially in developing countries and has become a major public health concern. This study evaluates the medical economic burden, including total current curative expenditure (CCE) and catastrophic health expenditure (CHE) on cancer in Liaoning Province, China. A total of 252 medical institutions were investigated with multistage stratified cluster random sampling. We established a standardized database of 3 532 517 samples. “System of Health Account 2011”, a new internationally recognized accounting system, was established to analyze the CCE on six most common cancers. CHE were estimated from the extracted 1344 patients with cancer, which performed a cross‐sectional study. The association of individual and contextual factors with CHE was evaluated using logistic regression models. CCE for all the patients with the six types of cancer was 2801.38 million CNY in Liaoning Province, the highest of which was lung cancer. The incidence of CHE was 42.78%, while the threshold was 40%. The average and relative distance were 10.41% and 24.32%, respectively. Influencing factors were length of stay, type of health insurance, location of household, etc. Our findings highlight the need to address medical economic burden in the cancer population. Households with the cancer are more likely to incur CHE. Financial intervention to prevent it should target on poor households. We provide suggestions in aspects of health insurance and health service management to reduce CHE.

show abstract

“…Overall in lower and middle income countries, health care expenditure accounts for between 13 to 32% of household expenditures, with one in four poor households in low income countries incurring potentially catastrophic health care expenses when family members become ill [11]. Between 41% and 56% of households in these countries spend 100% of health care expenditures on drugs [11][12][13][14]. We did not include Brazil and China, for example, because the nature of inappropriate use, including drivers,' is still surfacing in its detail.…”

Section: Approachmentioning

confidence: 99%

Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review

et al. 2015

View full text Add to dashboard Cite

Pharmaceutical expenditure has increased rapidly across many OECD countries over the past three decades. This growth is an increasing concern for Governments and other third party payers seeking to provide equitable and comprehensive healthcare within sustainable budgets. In order to create headroom for increasing utilisation, and to fund new high cost therapies there is an active push to 'disinvest' from low-value drugs. The aim of this article is to review how reimbursement policy decision makers have sought to partially or completely disinvest from drugs in a range of OECD countries (UK, France, Canada, Australia and New Zealand) where they are publicly funded or subsidised. We employed a systematic literature search strategy and the incorporation of grey literature known to the authorship team. We canvass key policy instruments from each country to outline: key approaches to the identification of candidate drugs for disinvestment assessment (passive approaches versus more active approaches); Methods of disinvestment and value-based purchasing:de-listing, restricting treatment, price or reimbursement rate reductions, encouraging generic prescribing; Lessons learnt from the various approaches; The potential role of coverage with evidence development, and; The need for careful stakeholder management. Dedicated sections are provided with detailed coverage of policy approaches (with drug examples) from each country. Historically countries have relied on 'passive disinvestment', however due to (i) the availability of new costeffectiveness evidence or (ii) 'leakage' in drug utilisation or (iii) market failure in terms of price competition, there is an increasing focus towards 'active disinvestment'. Isolating low-value drugs that would create headroom for innovative new products to enter the market is also motivating disinvestment efforts by multiple parties, including industry. Historically disinvestment has mainly taken the form of price reductions, especially when market failures are perceived to exist, and restricting treatment to sub-populations, particularly when a drug is no longer considered value for money. There is considerable experimentation internationally in mechanisms for disinvestment and the opportunity for countries to learn from each other. Ongoing evaluation of disinvestment strategies is essential, and ought to be reported in the peer-reviewed literature.

show abstract

Financial burden of household out-of pocket health expenditure in Viet Nam: Findings from the National Living Standard Survey 2002–2010

Cited by 191 publications

References 7 publications

An analysis of out-of-pocket costs associated with hospitalised injuries in Vietnam

An analysis of out-of-pocket costs associated with hospitalised injuries in Vietnam

How great is current curative expenditure and catastrophic health expenditure among patients with cancer in China? A research based on “System of Health Account 2011”

Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review

Contact Info

Product

Resources

About